Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Durvalumab with Gemcitabine and Oxaliplatin in Advanced Biliary Tract Cancer.

Cancers·2026

Same author

Optimal intraoperative management in pancreatic surgery: a systematic review of randomized controlled trials.

HPB : the official journal of the International Hepato Pancreato Biliary Association·2026

Same author

ASO Visual Abstract: AFP Model Predicts Outcomes after Liver Resection: a Multicenter Retrospective Cohort Study.

Annals of surgical oncology·2026

Same author

AFP Model Predicts Outcomes After Liver Resection: A Multicenter Retrospective Cohort Study.

Annals of surgical oncology·2026

Same author

Fibulin-4 expressed in metastatic breast cancer is a target of peptide-based imaging probes and experimental therapeutics.

Molecular therapy. Oncology·2026

Same author

Investigating machine learning algorithms to classify label-free images of pancreatic neuroendocrine neoplasms.

Biophotonics discovery·2026

Search research articles

Related Experiment Video

Updated: May 31, 2025

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

SSTR2-Targeted Theranostics in Hepatocellular Carcinoma.

Majid Momeny¹, Solmaz AghaAmiri¹, Servando Hernandez Vargas¹

¹The Brown Foundation Institute of Molecular Medicine, McGovern Medical School, The University of Texas Health Science Center, Houston, TX 77054, USA.

|January 25, 2025

Summary

Somatostatin receptor 2 (SSTR2)-targeted theranostics show promise for hepatocellular carcinoma (HCC). This study confirms SSTR2 expression in HCC and demonstrates the diagnostic and therapeutic potential of radiolabeled analogs for detecting and treating this cancer.

Keywords:

SSTR2 hepatocellular carcinoma theranostics

More Related Videos

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Related Experiment Videos

Last Updated: May 31, 2025

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Area of Science:

Oncology
Nuclear Medicine
Radiopharmaceutical Therapy

Background:

Radiolabeled somatostatin analogs are established for neuroendocrine tumors.
There is increasing interest in SSTR2-targeted agents for other cancers.
This study explores SSTR2 theranostics in hepatocellular carcinoma (HCC).

Purpose of the Study:

To evaluate the expression of somatostatin receptor 2 (SSTR2) in hepatocellular carcinoma (HCC).
To assess the diagnostic and therapeutic potential of SSTR2-targeted radiopharmaceuticals in HCC.
To investigate the combination of SSTR2-targeted therapy with sorafenib in HCC.

Main Methods:

SSTR2 expression was analyzed in HCC cell lines and clinical samples using qRT-PCR, Western blot, and public data.
Radioligand uptake (⁶⁷Ga-DOTATATE), cytotoxicity (¹⁷⁷Lu-DOTATATE), and tumor targeting (⁶⁸Ga-DOTATATE PET/CT) were evaluated.
Animal models and a patient with HCC were used for in vivo imaging and therapeutic assessment.

Main Results:

SSTR2 expression was confirmed in HCC cell lines and patient samples.
⁶⁷Ga-DOTATATE showed SSTR2-mediated uptake in HCC.
¹⁷⁷Lu-DOTATATE reduced HCC cell proliferation and enhanced sorafenib's anti-tumor effect.
⁶⁸Ga-DOTATATE PET/CT successfully identified HCC tumors and metastases.

Conclusions:

SSTR2-based theranostics demonstrate significant potential for HCC detection and treatment.
These findings support the clinical utility of SSTR2-targeted agents in managing hepatocellular carcinoma.